GBR-12783

GBR-12783 is a stimulant drug which acts as a dopamine reuptake inhibitor, selectively inhibiting the reuptake of dopamine into neurons, thus increasing the level of active dopamine in the brain. It was developed in the late 20th century by a team of researchers at the French pharmaceutical company Sanofi-Aventis.

Pharmacology

GBR-12783 inhibits the reuptake of dopamine by binding to the dopamine transporter (DAT), which is responsible for the reuptake of dopamine into neurons following its release. This results in an increase in the concentration of dopamine in the synaptic cleft, leading to increased dopamine activity.

Clinical significance

GBR-12783 has been used in scientific research to study the role of dopamine in the brain, and the effects of increased dopamine activity. It has been used in studies investigating conditions such as Parkinson's disease, schizophrenia, and drug addiction, where dopamine activity is thought to be involved.

Side effects

As with other drugs that increase dopamine activity, side effects of GBR-12783 can include restlessness, insomnia, and psychosis. However, these side effects are generally rare and occur primarily at high doses.

See also

• Dopamine reuptake inhibitor
• Dopamine transporter
• Sanofi-Aventis

References

GBR-12783 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia